HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.

AbstractOBJECTIVE:
The combination of hypertriglyceridemia and low high density lipoprotein (HDL) cholesterol is one of the most common lipid abnormalities. Thus, the aim of this study was to determine the effects of ciprofibrate on lipid profile in patients with Frederickson's type IV dyslipidemia phenotype.
RESEARCH DESIGN AND METHODS:
Seventy-five patients with type IV dyslipidemia were assigned at random to 1 of 2 therapeutic options: group A (control), American Heart Association (AHA) Step II diet and physical activity; and group B, AHA diet, physical activity, and ciprofibrate 100 mg daily for 8 weeks. The lipid profile of all patients was determined at baseline and after therapeutic intervention.
RESULTS:
Patients in group B (treated with ciprofibrate) compared with group A (control) had significantly higher reductions in total cholesterol (downward arrow 14.2% vs. downward arrow 4.8%; P < 0.02), triglycerides (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), very low density lipoprotein cholesterol (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), non-HDL cholesterol (downward arrow 20.5% vs. downward arrow 7.1%; P < 0.007), and total cholesterol/high density cholesterol ratio (downward arrow 25.6% vs. downward arrow 9.4%; P < 0.01). The ciprofibrate group had a significantly higher increase in HDL cholesterol levels compared with the other group (upward arrow 25.0% vs. upward arrow 9.6%, P < 0.02).
CONCLUSIONS:
Ciprofibrate treatment effectively reduced triglyceride-rich particles and non-HDL cholesterol, and significantly increased HDL cholesterol, proving its effectiveness in patients with low HDL cholesterol and type IV Frederickson's hyperlipidemia.
AuthorsValmore Bermúdez-Pirela, Aida Souki, Clímaco Cano-Ponce, Fernando Bermúdez-Arias, Edgardo Mengual-Moreno, Elliuz Leal-Gonzalez, Miguel Lemus-Antepaz, Mayela Cabrera de Bravo, Anilsa Amell de Díaz, Nilka Leal de Pirela, Raquel Cano-Peñaloza, Guillermo Puche-Medina, Navlet Arraiz, Nadia Reyna-Villazmil, Freddy Contreras, Zafar H Israili, Manuel Valasco
JournalAmerican journal of therapeutics (Am J Ther) 2007 Mar-Apr Vol. 14 Issue 2 Pg. 213-20 ISSN: 1075-2765 [Print] United States
PMID17414592 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Fibric Acids
  • Hypolipidemic Agents
  • Triglycerides
  • Clofibric Acid
  • ciprofibrate
Topics
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Cholesterol, VLDL (blood)
  • Clofibric Acid (analogs & derivatives, pharmacology, therapeutic use)
  • Female
  • Fibric Acids
  • Humans
  • Hyperlipoproteinemia Type IV (drug therapy)
  • Hypolipidemic Agents (pharmacology, therapeutic use)
  • Male
  • Middle Aged
  • Phenotype
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: